Global /United States /Healthcare /Medical Devices /BLFS
chevron_leftBack
BioLife Solutions, Inc. logo

BioLife Solutions, Inc.

BLFS
NASDAQ: BLFS Delayed
19.99USD -4.4%
As of 13 June 2026, BioLife Solutions, Inc. has a market cap of $965.52M USD, ranking #10888 globally and #2186 in the United States. It ranks #976 in the Healthcare sector, and #194 in the Medical Devices industry.
Global Rank
10888
Country Rank
2186
Sector Rank
976
Industry Rank
194
Key Stats
Market Cap
$965.52MUSD
Enterprise Value
$863.24MUSD
Revenue (TTM)
$96.21MUSD
EBITDA (TTM)
$3.61MUSD
Net Income (TTM)
-$4.6MUSD
EBITDA Margin
3.7%
Profit Margin
-4.8%
Forward PE
156.2
PS Ratio
10.0
PB Ratio
2.6
EV/EBITDA
239.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Roderick de Greef open_in_new
Employees
155
Founded
1987
IPO
22 Nov 1989
Website
biolifesolutions.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-4.4% -9.4% 9% -12% -28% -17%

News

Loading...

BLFS Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
BLFS
BioLife Solutions Inc
ISIN: US09062W2044
Shares Out.:
48.857M1 Shares Float: 46.843M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
19.99 USD
Frankfurt Stock Exchange
MIC: XFRA
BJX1
BioLife Solutions Inc
ISIN: US09062W2044
TV:
SA:
YF:
GF:
BA:
MS:
17.70 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About BioLife Solutions, Inc.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Similar Companies

Industry: Medical Devices (United States)
Name
Market Cap diff.
PE
$173.27B
18K%
25.8
$160.73B
17K%
56.7
$159.07B
16K%
25.6
DHR
$126.55B
13K%
34.7
SYK
$120.69B
12K%
38.3
$84.93B
9K%
24.5
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
MDT
$101.9B
10K%
22.2
$97.46B
84.32B EUR
10K%
36.7
7741
$61.41B
9.83T JPY
6K%
40.0
$45.47B
39.34B EUR
5K%
18.7
ALC
$36.38B
28.99B CHF
4K%
37.9
$30.06B
203.66B CNY
3K%
26.0
chevron_leftBack